EPZM : Summary for Epizyme, Inc. - Yahoo Finance

We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. Markets close in 2 hrs 11 mins

Epizyme, Inc. (EPZM)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
11.40 0.00 (0.00%)
At close: 4:00PM EST
People also watch
OMED XLRN AGIO ENTA KPTI
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close 11.40
Open 11.50
Bid 0.00 x
Ask 0.00 x
Day's Range 11.15 - 11.70
52 Week Range 7.02 - 13.46
Volume 194,712
Avg. Volume 315,837
Market Cap 661.33M
Beta 2.31
PE Ratio (TTM) -6.21
EPS (TTM) -1.84
Earnings Date Mar 7, 2017 - Mar 13, 2017
Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 23.33
Trade prices are not sourced from all markets
  • Pluristem (PSTI) Intermittent Claudication Study Enrolled
    Zacks 3 days ago

    Pluristem (PSTI) Intermittent Claudication Study Enrolled

    Pluristem Therapeutics (PSTI) has completed patient enrollment in a phase II study on PLX-PAD cells for the treatment of intermittent claudication.

  • TherapeuticsMD's Rejoice Study Data Published in Journal
    Zacks 4 days ago

    TherapeuticsMD's Rejoice Study Data Published in Journal

    TherapeuticsMD, Inc. (TXMD) announced the publication of two manuscripts detailing with the results of the company's pivotal phase III study (Rejoice) in Menopause: The Journal of The North American Menopause Society.

  • American City Business Journals 6 days ago

    New England Venture Capital Association adds new board members

    The New England Venture Capital Association announced the addition of five new board members Tuesday, with a focus on investors who have a background in the digital health and biotech industries. "With the additions boasting deep, specific focuses in biotech company creation, pharmaceuticals, and digital health, the appointments support a growing focus on the Life Sciences community, and come at a time when the organization continues to broaden its offerings in that sector," NEVCA said in a press release announcing the moves. New board members have connections to public companies like Johnson & Johnson (JNJ), Alnylam (ALNY) and Epizyme (EPZM), as well as top local venture capital firms like Atlas Venture, Bain Capital Ventures and Flybridge Capital.

  • AbbVie's HCV Combo Favorable in Japanese Phase III Study
    Zacks 6 days ago

    AbbVie's HCV Combo Favorable in Japanese Phase III Study

    AbbVie Inc. (ABBV) announced positive top-line data from a phase III study on its pan-genotypic ribavirin (RBV)-free regimen of glecaprevir/pibrentasvir (G/P) in Japanese patients.

  • Puma (PBYI) Expands Study Cohort for Lead Candidate PB272
    Zacks 7 days ago

    Puma (PBYI) Expands Study Cohort for Lead Candidate PB272

    Puma Biotechnology, Inc. (PBYI) has expanded the fourth cohort of the phase II SUMMIT study evaluating its lead candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating HER2 mutation (basket study).

  • Vertex Pharma Issues Disappointing 2017 Orkambi Outlook
    Zacks 7 days ago

    Vertex Pharma Issues Disappointing 2017 Orkambi Outlook

    Vertex Pharmaceuticals Incorporated (VRTX) announced preliminary financial results for 2016 and issued a financial outlook for 2017 on Jan 8, ahead of a Jan 9 presentation at the JP Morgan healthcare conference in San Francisco.

  • Zacks 28 days ago

    Moving Average Crossover Alert: Epizyme (EPZM)

    Epizyme, Inc. (EPZM) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

  • Should You Add Epizyme Inc (EPZM) to Your Portfolio?
    Insider Monkey last month

    Should You Add Epizyme Inc (EPZM) to Your Portfolio?

    There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Carl Icahn and George Soros think. Those hedge fund operators make billions of dollars each […]

  • Epizyme Tazemetostat Gets Fast Track Designation in U.S.
    Zacks 2 months ago

    Epizyme Tazemetostat Gets Fast Track Designation in U.S.

    Epizyme, Inc.'s (EPZM) lead pipeline candidate, tazemetostat (an EZH2 inhibitor), has received Fast Track designation in the U.S.

  • Benzinga 2 months ago

    Good And Bad News from Epizyme; Wedbush Analyst Weighs In

    Wedbush analyst David Nierengarten reiterated his Outperform rating on Epizyme Inc (NASDAQ: EPZM ) after the company announced that the FDA has granted fast track designation for tazemetostat in patients ...